Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Kymab Limited
Kymab Limited The Bennet Building b930

Kymab Limited patents


Recent patent applications related to Kymab Limited. Kymab Limited is listed as an Agent/Assignee. Note: Kymab Limited may have other listings under different names/spellings. We're not affiliated with Kymab Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "K" | Kymab Limited-related inventors


Antibodies and immunocytokines

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising the antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in the methods.... Kymab Limited

Synergistic combinations of ox40l antibodies for the treatment of gvhd

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.... Kymab Limited

Antibodies, uses & methods

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.... Kymab Limited

Methods, regimens, combinations & antagonists

The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.... Kymab Limited

Antibodies, variable domains & chains tailored for human use

The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate... Kymab Limited

Anti-light antibodies

The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.... Kymab Limited

Selective nav protein binders

The invention provides antibodies and fragments thereof which bind to human Nav1.7, as well as nucleic acids, vectors, host cells and hybridomas for making the same. Further provided are pharmaceutical compositions for use in treating, preventing and/or reducing the risk of a NAV1.7-mediated conditions or diseases, such as pain, inflammation,... Kymab Limited

Anti-light antibodies

The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.... Kymab Limited

Methods, cells & organisms

The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (e.g., in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a... Kymab Limited

Synergistic combinations of ox40l antibodies for the treatment of gvhd

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules - track 1

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.... Kymab Limited

Antibodies, uses & methods

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.... Kymab Limited

Synergistic combinations of ox40l antibodies for the treatment of gvhd

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.... Kymab Limited

Antibodies, uses & methods

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.... Kymab Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Kymab Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kymab Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###